Identifying cardiovascular (CV) risks early in drug development is essential, especially for detecting arrhythmias and hemodynamic changes. Despite this, many nonclinical toxicology studies still rely on brief, restraint-based ECG and blood pressure measurements that often miss the timing of peak d...
Page:
of
19